ProCE Banner Activity

Shifting the Paradigm in Hemophilia Care: Practical Insights Into Integrating Non-Factor Therapies

Clinical Thought

As the treatment landscape for hemophilia continues to evolve, non-factor therapies have emerged as a transformative option for both hemophilia A and B, with or without inhibitors. These therapies not only provide effective bleed prevention but also reduce treatment burden and open new doors for individualized care.

Released: May 16, 2025

Expiration: May 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group and Novo Nordisk, Inc.

Genentech, a member of the Roche Group

Novo Nordisk Inc

Faculty Disclosure

Primary Author

Justin Arnall, PharmD, FCCP, BCOP, has no relevant financial relationships to disclose.

Guy Young, MD: consultant/advisor/speaker: ASC Biotherapeutics, BioMarin, CSL Behring, Genentech/Roche, Hema Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi Genzyme, Spark, Takeda.